Safety and efficacy of ablative fractional CO2 laser thrapy for external genital and the vagina in women with breast cancer

Not Applicable

Completed

• Conditions: Symptom of vulvovaginal atrophy caused from low estrogen state

• Registration Number: JPRN-UMIN000027742
• Lead Sponsor: Medical corporation LEADING GIRLS

Brief Summary

Vaginal discomfort improved in all treated patients. The improvement in urinary tract symptoms was not significant, but in some patients there was a dramatic improvement. No serious side effects were observed.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-06-13
• Study Completion: 2018-09-30
• Last Update Posted: 2023-10-17

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 7

Inclusion Criteria

Not provided

Exclusion Criteria

1) heart disease 2) severely lung disease 3) pelvic organ prolapse (more than 3) 4) pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect of AFLT on breast cancer patients at pre, 3 months, 6 months and one year by questionnaire

Secondary Outcome Measures

Name	Time	Method
Effect of AFLT on breast cancer patients at pre, 3 months, 6 months and one year by objective evaluation and questionnaire.